REVIEW ARTICLES

Multiple intracellular signallings involved in regulation of ion channels by GH releasing or inhibitory hormones in pituitary somatotropes*

CHEN Chen (陈 晨)

Endocrine Cell Biology, Prince Henry's Institute of Medical Research, P. O. Box 5152, Clayton, Victoria 3168, Australia

Received July 21, 2000; revised August 8, 2000

Influx of Ca²⁺ via Ca²⁺ channels is the major step triggering exocytosis of pituitary somatotropes to release growth hormone (GH). Voltage-gated Ca²⁺ and K⁺ channels, the primary determinants of the influx of Ca²⁺ in somatotropes, are regulated by GH-releasing hormone (GHRH) and somatostatin (SRIF) through G protein-coupled signalling systems. Using whole-cell patch-clamp techniques, the changes of the Ca2+ and K+ currents in primary cultured somatotropes were recorded and signalling systems were studied using pharmacological reagents and intracellular dialysis of non-permeable molecules including antibodies and antisense oligonucleotides. GHRH increased both L-and T-types Ca^{2+} currents and decreased transient (I_A) and delayed rectified (I_K) K^+ currents. The increase in Ca^{2+} currents by GHRH was mediated by cAMP/protein kinase A system but the decrease in K* currents required normal function of protein kinase C system. The GHRH-induced alteration of Ca2+ and K+ currents augments the influx of Ca2+, leading to an increase in the [Ca²⁺] i and the GH secretion. In contrary, a significant reduction in Ca²⁺ currents and increase in K* currents were obtained in response to SRIF. The ion channel response to SRIF was demonstrated as a membrane delimited pathway and can be recorded by classic whole-cell configuration. Intracellular dialysis of anti-ai, antibodies attenuated the increase in K+ currents by SRIF whereas anti-ao antibodies blocked the reduction in the Ca2+ current by SRIF. Dialysis of antisense oligonucleotides specific for an sub-units also attenuated the inhibition of SRIF on the Ca2+ current. The Gia protein mediated the increase in K+ currents and the Go, protein mediated the reduction in the Ca2+ current by SRIF. The SRIF-induced alteration of Ca2+ and K+ currents diminished the influx of Ca2+, leading to a decrease in the [Ca2+] i and the GH secretion. It is therefore concluded that multiple signalling systems are employed in the ion channel response to CHRH or SRIF in somatotropes, which leads to an increase or decrease in the CH secretion.

Keywords: GHRH, somatostatin, G protein, cAMP, protein kinases.

Growth hormone-releasing hormone (GHRH) has been shown to stimulate GH secretion in several species since it was identified about two decades $ago^{[1,\,2]}$. It is generally accepted that exocytosis of growth hormone (GH) from somatotropes is regulated by intracellular free Ca^{2+} concentration ($[Ca^{2+}]i$). GHRH increases the $[Ca^{2+}]i$ in pituitary somatotropes, an effect that is totally abolished by using extracellular Ca^{2+} free solution or by the blockade of Ca^{2+} channels $[a^{2-5}]$. The large Ca^{2+} concentration gradient across the cell membrane allows a significant increase in the $[Ca^{2+}]i$ when membrane Ca^{2+} channels are opened. It has been shown that GHRH depolarises the membrane potential of pituitary somatotropes and increases the frequency of action potentials $[a^{6-7}]$. The majority of Ca^{2+} channels on the membranes of somatotropes are voltage-gated and the depolarisation or generation of action potential by GHRH would be expected to trigger an influx of Ca^{2+} . Since most of the

^{*} Project mainly supported by Australian National Health and Medical Research Council and partially supported by USA Human Growth Foundation and Aza Research Inc., Australia.

ionic currents across the membrane at resting potential are carried by K^+ , the transmembrane K^+ channels are thought to play an important role in GHRH-induced depolarization^[7,9~11]. GHRH indeed decreases membrane voltage-gated K^+ currents^[12,13]. The effect of GHRH on the membrane ion channels is most probably mediated by second messenger systems. This is because electrophysiological responses to GHRH cannot be observed with classical whole-cell recording (WCR) but do occur during microelectrode intracellular recording^[6], on-cell patch-clamp recording^[14] or nystatin-perforated recording^[7,9,12], when intracellular macromolecular second messenger systems remain undisturbed. In order to clarify the signalling systems employed by GHRH on voltage-gated Ca^{2+} and K^+ channels, patch clamp techniques have been employed to record the channel responses to GHRH in primary cultured ovine and human somatotropes.

Somatostatin (SRIF) is a well-defined inhibitor for the secretion of GH from pituitary somatotropes. A number of different ion channels in the somatotrope cell membrane have been demonstrated to be modified by somatostatin which leads to a reduction in the GH secretion^[15]. One important action of SRIF is to increase K⁺ currents leading to a hyperpolarisation of membrane potential and facilitate the repolarisation after action potential [16, 17]. These modifications of cell electrophysiological properties reduce the influx of Ca²⁺ via voltage-gated Ca²⁺ channels. The other important action of SRIF is to directly decrease transmembrane Ca2+ currents which has been observed in rat somatotropes^[8, 18] and neurones^[19, 20]. It has been suggested that G-proteins mediate both effects on the basis of blockade of the response by pertussis toxin treatment [8, 19, 20] and on the structure of a typical G-protein-coupled receptor^[21]. Subtypes of SRIF receptors are thought to be coupled to different types of G-proteins^[21] and the Gi protein is thought to mediate the effect of SRIF on K⁺ channels^[22]. Although Go protein has been suggested to play a role in the effect of SRIF to reduce Ca2+ currents and Gi protein has been suggested to increase K+ currents in GH3 tumour cell lines [22, 23], it is not clear as to which G-protein subtype mediates the effect of SRIF on membrane Ca2+ and K+ currents in 'normal' primary cultured somatotropes. The present study aimed at resolving this issue by dialysis of antibodies against a sub-unit of G protein and antisense oligonucleotides against a sub-unit of G protein mRNA sequence into cells to block the function of certain sub-type of G proteins. In primary cultured ovine somatotropes, we found that ai3 sub-unit of Gi3 protein mediates the increase in the K+ current and the αo_2 sub-unit of Go_2 protein mediates the reduction in the Ca^{2+} current by SRIF.

1 Effect of GHRH on voltage-gated Ca²⁺ and K+ currents

1.1 Ca²⁺ currents

The ovine somatotrope cultures were perfused with a bath solution containing 2.5 mmol/L Ca^{2+} , 130 mmol/L TEACl and 1 μ mol/L TTX, to exclude K^+ and sodium currents. Ca^{2+} currents were recorded using nystatin-perforated Cs^+ -internal whole-cell recording configuration.

Ovine somatotropes were found to have nifedipine-sensitive L-type Ca^{2+} currents and a low threshold transient T-type current. Recorded by nystatin perforated WCR, application of GHRH increased the amplitude of total Ca^{2+} currents to 146% of the control (P < 0.05) without modification of the activation properties (Fig. 1). The Ca^{2+} currents returned to control level about 20 min after removal of GHRH from bath solution (Fig. 1(b)). T-type Ca^{2+} currents were isolated by adding

of GHRH from bath solution for $20 \text{ min}^{[7]}$.

holding potential of -80 mV to +10 mV were

applied repeatedly at intervals of 10 s before and

after GHRH application. The increase in Ca²⁺


current per unit membrane capacitance (pF) oc-

curred about 30 s after GHRH application and

became maximal by 2 ~ 3 minutes^[7]. Incubation

of cells with Rp-cAMP (100 µmol/L), a mem-

brane permeable cAMP antagonist, for 10 min



Effect of GHRH on total Ca2+ currents. (a) From a Fig. 1 holding potential of -80 mV, depolarising pulses were applied as indicated at the bottom of the figure with a time interval of 3s between pulses. Upper current traces were recorded in control bath solution and middle current traces were recorded after the addition of GHRH (10 nmol/L) to the bath solution. (b) The currentvoltage relationship obtained by plotting peak current against voltage of depolarising pulses in control () GHRH-containing () and 20 min after removal of GHRH from (A) bath solution. Adapted from Ref. [7] with permission.

did not change the Ca2+ current but totally prevented its response to GHRH (Fig. 2(a)). H₈₉, a selective PKA inhibitor, at a concentration of 200 nmol/L did not modify the voltage-gated Ca²⁺ current but also prevented the Ca²⁺ current response to GHRH (Fig. 2(b)). PKC inhibitors, such as calphostin C or chelerythrine did not change the levels of voltage-gated Ca²⁺ current or the Ca²⁺ response to GHRH.




Fig. 2 Involvement of cAMP-PKA system in the Ca2+ current response to GHRH. Statistical data (mean ± s.e.m., n=5) for the Ca²⁺ current evoked by depolarizing pulse from a hp of -80 mV to +10 mV. The application of (a) 100 μmol/L Rp-cAMP or (b) 1 μmol/L H₈₀ did not significantly modify the recorded Ca²⁺ current. Both reagents, however, prevented GHRH from increasing the amplitude of the Ca²⁺ current. In the continued presence of Rp-cAMP or H_{89} , the amplitude of the Ca^{2+} current was unaffected by removal of GHRH.

1.2 K+ currents

The human somatotropes were perfused with a bath solution containing 0.5 mmol/L Ca^{2+} , 1 mmol/L Cd^{2+} and 1 μ mol/L TTX, to exclude Ca^{2+} and Na^+ currents. The K^+ currents were recorded using nystatin-perforated, K^+ -internal recording configuration.

When the K⁺ currents were recorded from the cells held at -80 mV and stepped to a range of test potentials (-50 ~ +60 mV at 10 mV increments over 400 ms), somatotropes were found to have a mixture of a voltage-gated transient K⁺ current (I_A) and a delayed rectified K⁺ current (I_K) . The large, transient I_A current was present when the somatotropes were held at -80 mV and stepped to potential above - 30 mV, but was absent when the cells were held at - 40 mV and stepped to the same test potential. Only the I_K current was recorded during the depolarising pulse when a holding potential of -40 mV was used. Application of GHRH evoked a significant reduction in the amplitude of the K+ current. The effect of GHRH occurred immediately, reaching the maximal reduction within 5 min, and the amplitude of the peak current recovered completely 10 min after the removal of GHRH. The total voltage-gated K⁺ current and I_K current were evoked by depolarising pulses from a holding potential of -80 mV and -40 mV, respectively. These two holding potentials were then used to differentiate between the two components of the K^+ current, I_A and I_K , respectively. Typical current traces of a somatotrope are shown in Fig. 3(a). Fig. 3(b) shows the current-voltage relationships for this cell first held at -80 mV (Fig. 3(b-i)) and then at -40 mV (Fig. 3(b-ii)). Means ± s.e.m. of current recorded with a test pulse to +60 mV from a group of 13 cells are shown in Fig. 3(c). GHRH treatment reduced I_A by 37.6% \pm 6.3% (hp = -80 mV, peak amplitude of the K^+ current) and I_K by 32.8% \pm 8.98% (hp = -40 mV, amplitude of steady-state K^+ current). Ten minutes after GHRH was removed and the cells perfused with bath solution, the peak amplitude of the I_A had fully recovered, whereas I_K was only partially recovered (88% of control). Several pharmacological reagents, such as 8-bromo-AMP (a membrane permeable cAMP analogue, 100 μmol/L), Rp-cAMP (a membrane permeable cAMP antagonist, 100 μmol/L), H₈₉ (a selective PKA inhibitor, 1 µmol/L) or internally dialysis of PKI (a selective PKA inhibitory peptide, 10 µmol/L) did not change either the recorded K+ current or the K+ current response to GHRH[12, 13].

Although the treatment of the somatotrope cultures with calphostin C for 10 min did not significantly change the mean amplitude of the peak K⁺ current, it abolished the GHRH-induced decrease in the K⁺ current amplitude (Fig. 4(a), n = 5). Similarly, incubation of the somatotropes with chelerythrine for 10 min did not affect the amplitude of total K⁺ current but preventing the GHRH-induced K⁺ current response (Fig. 4(b), n = 4). Pre-treatment of cells with phorbol 12, 13-dibutyrate (PDBu) for 16 h was used to down-regulate PKC systems in the cultured cells as we have used previously^[24]. Pre-treatment of cells with 4α -phorbol 12, 13-didecanoate (4α PDD) for 16 h was used as a control treatment as this phorbol has no biological activity^[25]. This down-regulation of PKC did not change the voltage-gated K⁺ current amplitude recorded with a test pulse to +60 mV from a hp of -80 mV (n = 6 for each group, Fig. 4(c)). The K⁺ current response to GHRH was, however, totally abolished in cells pre-treated with PDBu. Treatment with 4α PDD had no effect on either the peak K⁺ current amplitude or the response to GHRH (Fig. 4(c)). In contrast, a short term stimulation of PKC by 0.5μ mol/L PDBu for 10 min significantly reduced total K⁺ current similar to that induced by

GHRH but without clear recovery even 20 min after removal of PDBu (Fig. 4(d)). Again, the control 4α PDD was without effect. PKC₁₉₋₃₆, a selective PKC inhibitory peptide, was dialyzed into the recorded cell at a concentration of 10 μ mol/L via classic WCR patch-clamp pipette. No change was found in the recorded K⁺ current amplitude following this dialysis but the K⁺ current response to GHRH was blocked (Fig. 4(e)). Under the same recording conditions but using a vehicle to replace PKC₁₉₋₃₆, GHRH induced a significant reduction in the total K⁺ current (Fig. 4(e)).




Fig. 3 Effect of GHRH on voltage-gated K* currents. (a) The voltage-gated K* currents of human somatotropes recorded using different hp of -80 mV or -40 mV. Data are shown for a representative cell. (i) The peak K⁺ current traces evoked by a depolarising pulse to +60 mV from a hp of -80 mV under control (curve 1), during application of 10 nmol/ L GHRH (curve 2), and 10 min after the removal of GHRH (curve 3). (ii) The steady state K+ current traces evoked by a depolarising pulse to +60 mV from a hp of -40 mV under control (curve 1), during application of 10 nmol/L GHRH (curve 2), and 10 min after the removal of GHRH (curve 3). (b) The current-voltage relationships of the peak or steady state K⁺ current recorded with a hp of -80 mV or -40 mV. Data were obtained from the same cell in panel (a). (i) Comparison of peak K+ currents at a hp of -80 mV during a depolarising pulse up to +60 mV with a 10 mV interval measured under control (\bigcirc) , during application of GHRH (\bigcirc) , and 10 min after the removal of GHRH (\triangle) . (ii) Comparison of steady state K⁺ currents at a hp of -40 mV during a depolarising pulse up to +60 mV with a 10 mV interval measured under control (\bigcirc), during application of GHRH (\square), and 10 min after the removal of GHRH (\triangle). Note that only a partial recovery after the removal of GHRH was observed when K⁺ current was recorded at a hp of -40 mV. (c) (i) Statistical data (mean \pm s. e. m., n = 13) for the peak K⁺ current measured following depolarising pulse to +60 mV from a hp of -80 mV. GHRH (10 nmol/L) significantly (**, P < 0.01) reduced the amplitude of the K⁺ current with a full recovery 10 min after removal of CHRH. (ii) Statistical data (mean \pm s. e. m., n = 5) for the steady state K⁺ current measured following depolarising pulse to +60 mV from a hp of -40 mV. GHRH (10 nmol/L) significantly (**, P < 0.01) reduced the amplitude of K* current with a partial recovery 10 min after removal of GHRH. Adapted from Ref. [12] with permission.

In summary, GHRH is shown to increase voltage-gated Ca^{2+} currents whereas to reduce voltage-gated K^+ currents in somatotropes. The increase in Ca^{2+} currents by GHRH is mediated by cAMP/PKA system and the decrease in K^+ currents by GHRH requires activation of PKC system. Those




Fig. 4 Involvement of PKC system in the K⁺ current response to GHRH. Statistical data (mean ± s.e.m., n = 5) for the K⁺ current evoked by depolarizing pulse from a hp of -80 mV to +60 mV. The applications of 100 nmol/L calphostin C (a) or 1 μmol/ L chelerythrine (b) did not significantly modify the recorded K⁺ current. Both calphostin C and chelerythrine prevented GHRH from reducing the amplitude of the K+ current. In the continued presence of calphostin C or chelerythrine, the amplitude of the K+ current was unaffected by removal of GHRH. (c) After pretreatment of cells with 4αPDD (0.5 μmol/L, open columns) or PDBu (0. 5 µmol/L, filled columns) for 16 h, voltage-gated K+ currents were recorded from two treatment groups (n = 6 for each group). Statistical data (mean \pm s.e.m., n = 6) for the K⁺ current evoked by depolarizing pulse from a hp of -80 mV to +60 mV. No difference in voltage-gated K+ currents was observed between two treatments under control condition. The application of GHRH (10 nmol/L) significantly and reversibly reduced the recorded K* current in 4aPDD-treated cells but did not modify the K* current in PDBu-treated cells. (d) Local application of PDBu (0.5 μmol/L, filled columns) but not 4αPDD (0.5 μmol/L, open columns) for 10 min from application pipette decreased the voltage-gated K^* current. Statistical data (mean \pm s.e.m., n = 6) for the K^* current evoked by depolarizing pulse from a hp of -80 mV to +60 mV are given in this panel. Note that the recovery of K+ current was not observed at least 20 min after removal of PDBu. (e) PKC inhibitory peptide, PKC₁₉₋₃₆, is not membrane permeable. An internal dialysis was therefore used to introduce it to the recorded cell. Conventional WCR configuration was employed in this study as detailed in the Materials and Methods. Columns in this panel show statistical data (mean \pm s.e.m., n = 4) for the K⁺ current evoked by depolarizing pulse from a hp of -80 mV to +60 mV. Inclusion of PKC₁₉₋₃₆ (10 µmol/L) in internal solution (filled columns) for 15 min did not significantly modify the recorded K* current and GHRH did not modify the amplitude of the K* current in presence of PKC19.36 in the recorded cells. In a group of cells recorded without PKC19.36 in electrode (open columns), GHRH reversibly reduced the K⁺ current. Adapted from Ref. [12] with permission.

signalling systems are illustrated in Fig. 5, which demonstrates a diversity of intracellular signalling systems employed by GHRH to regulate voltage-gated Ca^{2+} or K^+ channels. Such an increase in Ca^{2+} current and decrease in K^+ current cause an elevation of Ca^{2+} influx and thereby the GH secretion.




Fig. 5 Mechanism of the action of GHRH on Ca²⁺ and K⁺ channels-coupling with PKA and PKC systems. This diagram illustrates the coupling of the Ca²⁺ and K⁺ channels with GHRH receptors. Using the extracellular and intracellular applied pharmacological reagents against different steps in PKA or PKC signalling systems, we have demonstrated that cAMP-PKA system mediates the action of GHRH on voltage-gated Ca²⁺ currents and PKC system is essential for the action of GHRH on voltage-gated K⁺ currents in somatotropes.

2 Effect of SRIF on voltage-gated Ca2+ and K+ currents

2.1 Ca²⁺ currents

As discussed above, two types of Ca²⁺ currents were recorded as T and L types with L current as the majority^[7]. Local administration of SRIF reduced both T and L currents without preference. We have shown that the reduction in Ca²⁺ currents by SRIF was completely abolished by the treatment of the culture with pertussis toxin (100 ng/mL) for 10 h^[8]. This result indicates that the functional expression of SRIF on Ca²⁺ currents is mediated through activation of pertussis toxin sensitive G proteins. We have also shown that [26] with WCR using anti-αo antibodies in the pipette, a reduction in Ca2+ currents by SRIF was obtained within 5 min after establishing WCR (Fig. 6). This response diminished after 20 min of dialysis of anti-αo antibodies, when SRIF was given a second time. With anti-αi₁₋₂, anti-αi₃ or heat-inactivated anti-αo antibodies in the electrode solution there was no effect on the reduction in Ca2+ currents by SRIF either just after WCR formation or after 20 min of dialysis (Fig. 6). In order to identify the subtype of Go proteins involved in the Ca²⁺ current response to GHRH, we developed antisense strategies to specifically target on ao1 or ao2 sub-units whereas the specific antibodies were not available [26]. At the time of dialysis with antisense oligonucleotides (1 μmol/L), recordings were made of voltage-gated Ca²⁺ currents and the response to SRIF. In order to study the time course of the effect of antisense dialysis, ao antisense (ASm) was dialysed into the cell when initial response to SRIF was recorded^[26]. Cell dialysis lasted for 5 min, which was sufficient for the dialysis of the antisense oligonucleotides. At the end of the dialysis period, the patch




Fig. 6 Effect of intracellular dialysis of anti- α sub-unit of G - protein antibodies on SRIF-induced reduction in Ca^{2+} current. Ca^{2+} current was evoked by depolarising pulses from a holding potential of -80 mV to 0 mV, with an electrode solution containing anti- α 0 sub-unit antibodies for intracellular dialysis (a). Ca^{2+} current was evoked by depolarising pulses from a holding potential of -80 mV to 20 mV with electrode solution containing anti- α 11-2 sub-unit antibody (b) or anti- α 3 sub-unit antibody (c) for intracellular dialysis. In (a) \sim (c), trace 1 represents the control current; trace 2 is the current after the first application of 10 nM SRIF; trace 3 is the current recorded about 20 min after establishing WCR; and trace 4 is the current after the second application of 10 nmol/L SRIF (following trace 3). (d) Ca^{2+} current-time relationships during intracellular dialysis of anti- α 3 sub-unit (\bigoplus), anti- α 0 sub-unit (\bigoplus) or anti- α 11-2 sub-units (\bigoplus) antibodies. Ca^{2+} current was recorded every min and shown as a percentage of control current (peak value, 100%). Numbers on the curve represent the times at which inward currents were passed to derive the data shown in panels (a) \sim (c). (e) (Mean \pm s.e.m.) percentage inhibition of peak Ca^{2+} current by 10 nmol/L SRIF during the first application of SRIF (filled columns) or 20 min after establishing WCR (open columns) during the intracellular dialysis with anti- α 0 (n = 8), anti- α 11-2 (n = 5), anti- α 13 (n = 8) or heat-inactivated anti- α 0 (n = 8) antibodies. $\alpha \times P < 0.01$. Adapted from Ref. [26] with permission.

pipette was carefully withdrawn, and usually the cell resealed itself. Distinctive marks were made on recorded dishes to locate the dialysed cells for subsequent recording. The cells were then incubated in the presence of serum for 12, 24, 48, and 72 h, the cells that survived dialysis were re-patched for a second time for the response to SRIF. A sharp reduction in the effect of SRIF on the Ca^{2+} current was observed after 24 h of incubation, reached a peak after 48 h incubation, and partially recovered after 72 h of incubation^[26]. The incubation time of 48 h was then selected to study the effect of different antisense oligonucleotides dialysis on the response to SRIF. After dialysis of α 0 ASm or α 0 AS, there was a reduced effect of SRIF on Ca^{2+} currents compared with the initial response to SRIF (Fig. 7). In contrast, after dialysis of α 3 AS or α 01 AS, the SRIF response was not altered (Fig. 7). No

kinetic changes were obtained after dialysis of antisense oligonucleotides.




Fig. 7 Ca^{2+} -current inhibition by SRIF in ovine somatotrophs 48 h after dialyses of antisense oligonucleotides directed against mRNAs encoding αo , $\alpha o 1$, $\alpha o 2$, and $\alpha i 3$ sub-units. Ca^{2+} current was evoked by depolarising pulses from a holding potential of -80 mV to 10 mV with an electrode solution containing $\alpha o 1$ AS (a) or $\alpha o 2$ AS (b) for intracellular dialysis. Trace 1 represents the control current; trace 2 is the current after the application of 10 nmol/L SRIF during initial recording; trace 3 is the current recorded 48 h after dialysis; and trace 4 is the current after the second application of 10 nmol/L SRIF. (c) (Mean \pm s. e. m.) percentage inhibition of peak Ca^{2+} current by SRIF during the dialysis of antisense oligonucleotides (filled columns) or 48 h after the dialysis (open columns) with αo ASm (n = 7), $\alpha o 1$ AS (n = 4), $\alpha o 2$ AS (n = 4), or $\alpha i 3$ AS (n = 5). **: P < 0.01. Adapted from Ref. [26] with permission.

2.2 K+ currents

SRIF causes a reversible increase in voltage-gated K⁺ currents including both I_A and I_K currents $^{[17,\ 27]}$. In ovine somatotropes, those two types of K⁺ currents were recorded with I_K as the majority $^{[27,\ 28]}$. Local administration of SRIF (10 nmol/L) increased both I_A and I_K without preference and this increase was reversible after removal of the SRIF $^{[27]}$. When the GTP- γ -s was included in the electrode solution (200 μ mol/L), application of SRIF increased the K⁺ currents but this increase was not reversible after removal of the SRIF. When the same concentration of GDP- β -s was included in the electrode solution, the increase in the K⁺ current by SRIF was totally abolished. These effects of GTP- γ -s and GDP- β -s dialyses on the K⁺ current response to SRIF strongly indicate an involvement of G-proteins.

With WCR using anti-αi₁₋₂ or anti-αi₃ antibodies in the pipette, an increase in K⁺ currents by SRIF was obtained within 5 min after establishing WCR (Fig. 8). This response diminished after

25 min of dialysis of anti- αi_3 antibodies, when SRIF was given a second time (Fig. 8). With anti- αi_{1-2} antibodies in the electrode solution there was no modification of the increase in K⁺ currents by SRIF either just after WCR formation or after 25 min of dialysis (Fig. 8). Dialysis of these antibodies did not change the basal K⁺ current recorded by depolarising membrane potentials from a holding potential of -80 mV. These data therefore indicate that Gi₃ protein mediates the action of SRIF on the voltage-gated K⁺ current^[27].

We conclude that the effect of SRIF on voltage-gated K^+ currents in ovine somatotropes is mediated by αi_3 sub-unit of Gi_3 proteins and on voltage-gated Ca^{2+} currents is by αo_2 sub-unit of Go_2 proteins. The mechanism of action of SRIF on Ca^{2+} and K^+ currents is summarised and illustrated in Figure 9.




Fig. 8 Effect of intracellular dialysis of anti- α i1-2 or anti- α i3 sub-units of G-protein antibodies on SRIF-induced increase in the K⁺ current. The K⁺ current was evoked by depolarizing pulses from a holding potential of -80 mV to +40 mV with an electrode solution containing anti- α i1-2 antibody (a) or anti- α i3 antibody (b). SRIF was applied twice within 5 min after establishing WCR and at 25 min after establishing WCR. Trace 'SRIF' is the current after the application of 10 nmol/L SRIF. (c) is the K⁺ current (calculated for unit membrane capacitance, pF) evoked by the same depolarising pulse with an electrode solution containing antibodies against α i1-2 or α i3 sub-unit of G-protein for intracellular dialysis. Data shown are mean(\pm s.e.m.) peak K⁺ current (marked by control) and the K⁺ current in presence of 10 nmol/L SRIF (marked by SRIF) during the first application of SRIF (5 min) or 25 min after establishing WCR (25 min) during the intracellular dialysis with anti- α i1-2 (n = 5), anti- α i3 (n = 8) antibodies. **: P<0.01. Adapted from Ref. [27] with permission.




Fig. 9 Mechanism of the action of SRIF on Ca^{2+} and K^{+} channels-coupling with Go_2 and Gi_3 proteins. This diagram illustrates the coupling of the Ca^{2+} and K^{+} channels with somatostatin receptors. Using the intracellular dialysis of antibodies and antisense oligonucleotides against different α sub-units of G proteins, we have demonstrated that αo_2 sub-unit of Go_2 protein mediates the action of SRIF on voltage-gated Ca^{2+} currents and αi_3 sub-unit of Gi_3 protein mediates the action of SRIF on voltage-gated K^{+} currents in ovine somatotrophs.

3 Final conclusion

Our study clearly demonstrated the modification of voltage-gated Ca²⁺ and K⁺ channels by GHRH and SRIF in opposite directions. The detailed signalling systems also have been studied using extracellular applied pharmacological reagents, intracellular applied peptidergic protein kinase inhibitors, antibodies or antisense oligonucleotides. Detailed studies of certain signalling molecules at single cell level are clearly able to resolve which signalling systems mediate which responses and the dialyses of specific peptidergic inhibitors, antibodies or/and antisense oligonucleotides via patch-clamp electrode provide a powerful approach in this regard. The technique of intracellular dialysis can also be used in other studies, such as direct dialysis of intracellular signalling molecules or the peptide fragment of receptor responsible for the cascade of stimulation by activation of the receptor.

Acknowledgment I would like to thank Drs. I. J. Clarke, R. Xu, S. Roh, J. Zhang, D. Wu, M. Pullar, and Ms. K. Loneragan for their contribution. I would also like to thank Ms. S. Panckridge for preparing graphics for this manuscript.

References

- 1 Guillemin, R. et al. Growth hormone releasing factor from a human pancreatic tumour that causes acromegaly. Science, 1982, 218: 585.
- 2 Spiess, J. et al. Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumour. Biochemistry, 1982, 21: 6037.
- 3 Cuttler, L. et al. Calcium signalling in single growth hormone-releasing factor-responsive pituitary cells. Endocrinology, 1992, 130, 945.
- 4 Holl, R. W. et al. Intracellular calcium concentration and growth hormone secretion in individual somatotropes: Effects of growth hormone-releasing factor and somatostatin. Endocrinology, 1988, 122: 2927.
- 5 Lussier, B. T. et al. Free intracellular Ca²⁺ concentration ([Ca²⁺]i) and growth hormone release from purified rat somatotropes. I. GH-releasing factor-induced Ca²⁺ influx raises [Ca²⁺]i. Endocrinology, 1991, 128: 570.
- 6 Chen, C. et al. Electrophysiological responses of rat pituitary cells in somatotroph-enriched primary culture to human growth hormone-releasing factor. Neuroendocrinology, 1989, 50: 679.

- 7 Chen, C. et al. Modulation of Ca²⁺ influx in the ovine somatotropes by growth hormone-releasing factor. American Journal of Physiology, 1995, 268: E204.
- 8 Chen, C. et al. Two types of voltage-dependent calcium currents in rat somatotrophs are reduced by somatostatin. Journal of Physiology, 1990, 425: 29.
- 9 Chen, C. et al. Human growth hormone releasing factor (hGRF) modulates calcium currents in human growth hormone secreting adenoma cells. Brain Research, 1993, 604; 345.
- Mollard, P. et al. Somatostatin blocks Ca²⁺ action potential activity in prolactin-secreting pituitary tumor cells through coordinate actions on K⁺ and Ca²⁺ conductance. Endocrinology, 1988, 123; 721.
- 11 Ohlsson, L. et al. Growth hormone-releasing factor induces a biphasic modulation of K* permeability in perfused cultured rat somatotropes. Acta Physiol. Scand., 1989, 137; 237.
- 12 Xu, R. et al. Human GHRH reduces voltage-gated K⁺ currents via a non-cAMP-dependent but PKC-mediated pathway in human GH adenoma cells. Journal of Physiology, 1999, 520: 697.
- 13 Xu, R. et al. Growth hormone-releasing hormone decreases voltage-gated potassium currents in GH4C1 cells. Journal of Neuroendocrinology, 2000, 12: 147.
- 14 Nussinovitch, I. Growth hormone releasing factor evokes rhythmic hyperpolarizing currents in rat anterior pituitary cells. Journal of Physiology, 1988, 395: 303.
- 15 Chen, C. et al. Ion channels and signal transduction pathways in the regulation of growth hormone secretion. Trends in Endocrinology and Metabolism, 1994, 5: 227.
- 16 Chen, C. et al. Electrophysiological responses to somatostatin of rat hypophysial cells in somatotroph-enriched primary cultures. Journal of Physiology, 1989, 408: 493.
- 17 Chen, C. et al. Somatostatin increases voltage-dependent potassium currents in rat somatotropes. American Journal of Physiology, 1990, 259: C854.
- 18 Nussinovitch, I. Somatostatin inhibits two types of voltage-activated calcium currents in rat growth hormone secreting cells. Brain Research, 1989, 504: 136.
- 19 Surprenant, A. et al. Inhibition of calcium currents by noradrenaline, somatostatin and opioids in guinea-pig submucosal neurones. Journal of Physiology, 1990, 431: 585.
- 20 Ikeda, S.R. et al. Somatostatin cyclic octapeptide analogs which preferentially bind to SOMa receptors block a calcium current in rat superior cervical ganglion neurones. Neuroscience Letter, 1989, 96: 283.
- 21 Bell, G.I. et al. Molecular biology of somatostatin receptors. Trends in Neuroscience, 1993, 16: 34.
- 22 Yatani, A. et al. Reconstitution of somatostatin and muscarinic receptor mediated stimulation of K* channels by isolated G_K protein in clonal rat anterior pituitary cell membranes. Molecular Endocrinology, 1987, 1: 283.
- 23 Kleuss, C. et al. Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents. Nature, 1991, 353: 43.
- 24 Wu, D. et al. The role of protein kinase C in GH secretion induced by GH-releasing factor and GH-releasing peptides in cultured ovine somatotropes. Journal of Endocrinology, 1997, 154; 219.
- 25 White, J. R. et al. Effect of phorbol 12-myristate 13-acetate and its analogue 4 alpha-phorbol 12,13-didecanoate on protein phosphorylation and lysosomal enzyme release in rabbit neutrophils. Journal of Biological Chemistry, 1984, 259; 8605.
- 26 Chen, C. et al. G(o)-2 protein mediates the reduction in Ca²⁺ currents by somatostatin in cultured ovine somatotropes. Journal of Physiology, 1996, 491: 21.
- 27 Chen, C. G_{i-3} protein mediates the increase in voltage-gated K* currents by somatostatin on cultured ovine somatotrophs. American Journal of Physiology, 1998, 275: E278.
- 28 Chen, C. et al. Voltage-dependent potassium currents in ovine somatotrophs and their function in growth hormone secretion. Neuroendocrinology, 1994, 59: 1.